Screener
Ligand Pharmaceuticals LGND Ohtuvayre inventors — Financial Royalty Assets, Allowance
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Qarziba | $101,303 | $(468) | $100,835 | $118,593 | $(498) | $118,095 |
| Agenus Bot/Bal | 40,815 | (408) | 40,407 | 40,815 | (408) | 40,407 |
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's ohtuvayre inventors — financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported ohtuvayre inventors — financial royalty assets, allowance of $179K in Q2 2026.
- What does ohtuvayre inventors — financial royalty assets, allowance mean?
- This metric represents the valuation allowance or reserve established against the royalty assets related to the Ohtuvayre product line to account for potential credit losses or impairment. It reflects management's assessment of the collectability and long-term value of the expected future royalty streams. A significant change in this allowance may indicate shifts in the perceived risk profile or commercial viability of the underlying asset.
Ask your AI about Ligand Pharmaceuticals's ohtuvayre inventors — financial royalty assets, allowance.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude